InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
4
T+90 hit rate
60%
T+90 mean return
-2.5%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Schneider Eugene, Vice-Président Exécutif. Director active across 1 company, notably Ionis Pharmaceuticals INC. Aggregated, 17 filings have been recorded. Breakdown: 0 buy · 4 sells. Total volume traded: €809k. History available since 15 October 2021. The latest transaction was filed on 19 March 2026 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Schneider Eugene
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations17 total
26,000 sharesCommon StockSEC:0000874015-26-000216:0
26,000 sharesCommon StockSEC:0000874015-26-000216:1
5,812 shares@ US$70.971520.4% of flowCommon StockSEC:0000874015-26-000152:0
19,658 shares@ US$53.7730.0% of flowCommon StockSEC:0000874015-25-000211:0
9,549 shares@ US$42.800416.6% of flowCommon StockSEC:0000874015-25-000172:0
4,032 shares0Common StockSEC:0000874015-25-000080:0
17,372 shares0Common StockSEC:0000874015-25-000064:0
2,106 shares@ US$49.596.8% of flowCommon StockSEC:0000874015-24-000197:0
4,033 shares0Common StockSEC:0000874015-24-000109:0
15,162 shares0Common StockSEC:0000874015-24-000077:0
8,000 shares@ US$32.6016.9% of flowCommon StockSEC:0000874015-24-000059:0
25,000 shares@ US$47.3476.3% of flowCommon StockSEC:0000874015-23-000240:0
4,033 shares0Common StockSEC:0000874015-23-000095:0
13,046 shares0Common StockSEC:0000874015-23-000068:0
416 shares0Common StockSEC:0000874015-22-000164:0
10,400 shares0Common StockSEC:0000874015-22-000051:0
417 shares0Common StockSEC:0000874015-21-000164:0
17 of 17 declarations
About Schneider Eugene
Eugene Schneider is the Executive Vice President and Chief Clinical Development Officer at Ionis Pharmaceuticals Inc. He oversees clinical development programs and plays a key role in the company's research strategy.
